Thomas A Hughes
Overview
Explore the profile of Thomas A Hughes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1529
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Websdale A, Kiew Y, Chalmers P, Chen X, Cioccoloni G, Hughes T, et al.
Biochem Pharmacol
. 2021 Aug;
196:114731.
PMID: 34407453
Cholesterol esterification proteins Sterol-O acyltransferases (SOAT) 1 and 2 are emerging prognostic markers in many cancers. These enzymes utilise fatty acids conjugated to coenzyme A to esterify cholesterol. Cholesterol esterification...
12.
Gwili N, Jones S, Al Amri W, Carr I, Harris S, Hogan B, et al.
Br J Cancer
. 2021 Jul;
125(7):983-993.
PMID: 34253873
Background: Breast cancer stem cells (BCSCs) are drivers of therapy-resistance, therefore are responsible for poor survival. Molecular signatures of BCSCs from primary cancers remain undefined. Here, we identify the consistent...
13.
Hsu S, Hui E, Liu M, Wu D, Hughes T, Smith J
PLoS One
. 2021 Jun;
16(6):e0252901.
PMID: 34161324
Nuclear receptors are a class of transcriptional factors. Together with their co-regulators, they regulate development, homeostasis, and metabolism in a ligand-dependent manner. Their ability to respond to environmental stimuli rapidly...
14.
Stevens W, Farrow I, Georgiou L, Hanby A, Perren T, Windel L, et al.
Br J Radiol
. 2021 Jun;
94(1123):20201396.
PMID: 34106751
Objectives: Better markers of early response to neoadjuvant chemotherapy (NACT) in patients with breast cancer are required to enable the timely identification of non-responders and reduce unnecessary treatment side-effects. Early...
15.
Armstrong G, Khot M, Tiernan J, West N, Perry S, Maisey T, et al.
Int J Exp Pathol
. 2021 May;
102(3):172-178.
PMID: 33951261
The transmembrane protein, c-Met, is thought to be overexpressed and activated in colorectal cancer (CRC). This study explored its potential as a diagnostic tissue biomarker for CRC in a large...
16.
Hutchinson S, Websdale A, Cioccoloni G, Roberg-Larsen H, Lianto P, Kim B, et al.
Oncogene
. 2021 Mar;
40(16):2872-2883.
PMID: 33742124
Triple negative breast cancer (TNBC) is challenging to treat successfully because targeted therapies do not exist. Instead, systemic therapy is typically restricted to cytotoxic chemotherapy, which fails more often in...
17.
Broad R, Jones S, Teske M, Wastall L, Hanby A, Thorne J, et al.
Br J Cancer
. 2021 Jan;
124(6):1110-1120.
PMID: 33398063
Background: Triple negative breast cancers (TNBC) have poor prognoses despite aggressive treatment with cytotoxic chemotherapy. Cancer-associated fibroblasts (CAFs) are prominent in tumour stroma. Our hypothesis was that CAFs modulate chemotherapy...
18.
Lakshmi S, Hughes T, Priya S
Eur J Cancer
. 2020 Dec;
144:252-268.
PMID: 33373870
Improved treatment of breast cancer, the world's second most common cancer, requires identification of new sensitive prognostic and diagnostic biomarkers. Exosomes are lipid-bilayer extracellular vesicles of size 30-150 nm, released...
19.
Yang Q, Hughes T, Kelkar A, Yu X, Cheng K, Park S, et al.
Elife
. 2020 Oct;
9.
PMID: 33103998
The Spike protein of SARS-CoV-2, its receptor-binding domain (RBD), and its primary receptor ACE2 are extensively glycosylated. The impact of this post-translational modification on viral entry is yet unestablished. We...
20.
Al Amri W, Baxter D, Hanby A, Stead L, Verghese E, Thorne J, et al.
Breast Cancer Res Treat
. 2020 Aug;
183(3):607-616.
PMID: 32734521
Purpose: More than a third of primary breast cancer patients are treated with cytotoxic chemotherapy, typically without guidance from predictive markers. Increased use of neoadjuvant chemotherapy provides opportunities for identification...